Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Collaborations
SAFC Biosciences, Vivalis complete first stage of R&D collaboration on viral vaccines
May 10th, 2006
SAFC Biosciences, a member of the Sigma-Aldrich Group (SIAL), and Vivalis, have announced the successful completion of the first stage of their ongoing collaboration with the launch of their EX-CELL EBx platform, which includes EX-CELL EBx viral growth and production media. This media is designed exclusively to support EBx cells, a chicken embryonic derived stem cell line, for growth and production of viral vaccines for therapeutic use. Under the R&D agreement, which began in 2004, SAFC Biosciences has developed and optimized media for use with Vivalis' widely licensed EBx cells, in the commercial development of viral vaccines for clinical trials and...
Source: Vaccine Weekly (2006-05-10)
|
